Finance

China biotech flag

Biotech

The Nasdaq’s newest ETF invites investors to bet on Chinese biopharma

By Rebecca Robbins

Pharmalot

Pharmalittle: Icahn dealt setbacks in bid to derail Cigna deal for Express Scripts; Pfizer suit against J&J proceeds

By Ed Silverman

advertisement

Pharmalot

Pharmalittle: FDA approved record number of generics in July; feds join suits against Suboxone maker

By Ed Silverman

advertisement

Pharmalot

Pharmalittle: Mylan is evaluating its options; GW will charge $32,500 for its cannabinoid for epilepsy

By Ed Silverman

Pharmacy Benefit Managers

Pharmalot

Express Scripts to drop dozens more drugs from its formulary next year

By Ed Silverman

Pharmalot

Pharmalittle: Icahn calls Cigna deal for Express Scripts ‘ridiculous’; U.K. may place price controls on biosimilars

By Ed Silverman

Pharmalot

Pharmalittle: Celgene raised prices in the U.S, but dropped them in Russia; Pain CEO criticizes ‘bizarre’ FDA rejection

By Ed Silverman

advertisement

Adam's Take

Geron’s prodigious fundraising activity signals low confidence in J&J relationship

By Adam Feuerstein

advertisement

Pharmalot

Pharmalittle: EMA to lose more staff than expected over Brexit move; Icahn objects to Cigna takeover of Express Scripts

By Ed Silverman

Pharmalot

Pharmalittle: Pfizer and FDA are mum on risky use of a drug; Bayer paid docs how much to tout Essure?

By Ed Silverman

A dosage of Spinraza.

Biotech

For UMass Medical School, Spinraza sales add millions to the budget

By Kate Sheridan

A photo of Venture capitalist Lisa Suennen.

Business

VCs are pouring money into digital health. Are they making smart bets?

By Rebecca Robbins and Adam Feuerstein

A photo of Lenny Parker and TJ Parker.

Business

At PillPack, a lot of credit goes to the father of invention

By Scott Kirsner — Boston Globe

The Readout LOUD

LISTEN: A debatable Alzheimer’s breakthrough, Gilead’s golden age, and separating smart money from dumb

By Damian Garde, Adam Feuerstein, and Rebecca Robbins

Doctors Food

Pharmalot

New Jersey looks to loosen restrictions on dinners for docs, giving pharma a victory

By Ed Silverman

Pharmalot

Pharmalittle: Glaxo buys a $300 million stake in 23andMe; CF patients sue for coverage

By Ed Silverman

Business

Biogen rare-disease drug bounces back with strong sales in the second quarter

By Adam Feuerstein

Adam's Take

Preclinical biotech companies are having an IPO bonanza. What’s the draw for investors?

By Adam Feuerstein

Pharmalot

Pharmalittle: Glaxo considers shedding its consumer unit; Amazon is eyeing a large pharmacy chain in India

By Ed Silverman

The Readout LOUD

LISTEN: Pharma at the midterms, CRISPR’s latest crack-up, and your guide to earnings

By Damian Garde, Adam Feuerstein, and Rebecca Robbins

Vacuum

Health

Health insurers are vacuuming up details about you. That could raise your rates

By Marshall Allen — ProPublica

Amazon PBM shopping

Business

In prescription drug business, will Amazon partner with PBMs, or seek to conquer them?

Pharmalot

Novartis is the latest big drug maker to exit antibiotic research

By Ed Silverman

Pharmalot

Pharmalittle: Sanofi closes a plant over environmental concerns; Azar promises changes to 340B

By Ed Silverman

Nasdaq

Biotech

Investors are bored with Big Biotech. Here’s a look at the numbers

By Damian Garde

Pharmalot

Pharmalittle: AstraZeneca gets a boost for its oncology biz; Takeda chief keeps stumping for Shire deal

By Ed Silverman

China Pharmacy

Business

How are drug makers going to make money in China? An explainer

By Rebecca Robbins

Pharmalot

Pharmalittle: E.U. health chief calls Trump freeloading claim ‘fake news’; one drug maker says no to Right to Try

By Ed Silverman

Pharmalot

Pharmalittle: A campaign downplays concerns over antibiotics given animals; U.K. parents step up fight over Vertex drug

By Ed Silverman